BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 33029633)

  • 1. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
    Kinoshita T; Hatake K; Yamamoto K; Higuchi Y; Murakami S; Terui Y; Yokoyama M; Maruyama D; Makita S; Hida Y; Saito T; Tobinai K
    Jpn J Clin Oncol; 2021 Jan; 51(1):70-77. PubMed ID: 33029633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
    Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
    Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
    Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
    Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
    Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
    Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
    Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
    Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
    Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Lu T; Gibiansky L; Li X; Li C; Shi R; Agarwal P; Hirata J; Miles D; Chanu P; Girish S; Jin JY; Lu D
    Leuk Lymphoma; 2020 Dec; 61(12):2905-2914. PubMed ID: 32705923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
    J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
    Advani RH; Lebovic D; Chen A; Brunvand M; Goy A; Chang JE; Hochberg E; Yalamanchili S; Kahn R; Lu D; Agarwal P; Dere RC; Hsieh HJ; Jones S; Chu YW; Cheson BD
    Clin Cancer Res; 2017 Mar; 23(5):1167-1176. PubMed ID: 27601593
    [No Abstract]   [Full Text] [Related]  

  • 13. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
    Choi Y; Diefenbach CS
    Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
    Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
    Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
    Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
    Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
    Topp MS; Eradat H; Florschütz A; Hochhaus A; Wrobel T; Walewski J; Knopinska-Posluszny W; Kanate AS; Lech-Maranda E; Brunnberg U; Chitra S; Nielsen TG; Sellam G; Shivhare M; Lossos IS
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):811-817. PubMed ID: 35182224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
    Smith SD; Lopedote P; Samara Y; Mei M; Herrera AF; Winter AM; Hill BT; Shadman M; Ujjani C; Lynch RC; Jacobson CA; Kim AI; Caimi P; Milano F; Gopal AK
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):170-175. PubMed ID: 33431309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Camus V; Tilly H
    Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.